Insider · CIK 0001830001
Josh Wolfe
Files at EIKN (Eikon Therapeutics, Inc.). First filing Feb 6, 2026, latest Feb 6, 2026.
In brief
Josh Wolfe files SEC Form 4 as director and 10% owner at EIKN (Eikon Therapeutics, Inc.). Since Feb 6, 2026, Josh Wolfe has reported 2 open-market buys worth $10.0M and 0 open-market sells worth $0, the latest filed on Feb 6, 2026.
A track record needs three past buys with six months of prices behind them; Josh Wolfe has 0, so none is measured yet.
The newest scored trade: bought $5.0M of EIKN on Feb 4, 2026, filed Feb 6, 2026, scored 63 (notable). In the last 12 months: 2 buys worth $10.0M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EIKN: Eikon Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 63Notable | Eikon Therapeutics, Inc. | $5.0M 277,776 shares | - | - | |
| 63Notable | Eikon Therapeutics, Inc. | $5.0M 277,776 shares | - | - |
Transactions
Every row this insider has filed, 30 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnote | +138,888 | $18.00 | $2.5M | 138,888 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +138,888 | $18.00 | $2.5M | 138,888 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnote | +138,888 | $18.00 | $2.5M | 138,888 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +138,888 | $18.00 | $2.5M | 138,888 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +2,387,705 | - | - | 2,387,705 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See footnote | +2,387,705 | - | - | 2,387,705 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +1,151,540 | - | - | 1,290,428 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See footnote | +1,151,540 | - | - | 1,290,428 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +2,155,765 | - | - | 2,294,653 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See footnote | +2,155,765 | - | - | 2,294,653 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series A Preferred Stockderivativeindirect: See Footnote | -10,000,000 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series A Preferred Stockderivativeindirect: See footnote | -10,000,000 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series A-1 Preferred Stockderivativeindirect: See Footnote | -7,807,026 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series A-1 Preferred Stockderivativeindirect: See footnote | -7,807,026 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series A-1 Preferred Stockderivativeindirect: See Footnote | -2,502,252 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series A-1 Preferred Stockderivativeindirect: See footnote | -2,502,252 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnote | -796,380 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: See Footnote | -796,380 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: See Footnote | -530,920 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnote | -530,920 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series B-1 Preferred Stockderivativeindirect: See Footnote | -5,289,322 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series B-1 Preferred Stockderivativeindirect: See footnote | -5,289,322 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series B-1 Preferred Stockderivativeindirect: See footnote | -3,526,215 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series B-1 Preferred Stockderivativeindirect: See Footnote | -3,526,215 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series C Preferred Stockderivativeindirect: See footnote | -303,360 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series C Preferred Stockderivativeindirect: See Footnote | -303,360 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series C-1 Preferred Stockderivativeindirect: See footnote | -1,450,614 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series C-1 Preferred Stockderivativeindirect: See Footnote | -1,450,614 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series D Preferred Stockderivativeindirect: See footnote | -10,266,152 | - | - | 0 | Feb 6, 2026 |
| Feb 6, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series D Preferred Stockderivativeindirect: See Footnote | -10,266,152 | - | - | 0 | Feb 6, 2026 |
Questions about Josh Wolfe
Answered from the filings on this page, as of the latest one.
Is Josh Wolfe buying or selling?
In the last 12 months Josh Wolfe reported 2 open-market buys worth $10.0M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $5.0M of EIKN on Feb 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Josh Wolfe's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Josh Wolfe has 0.
Where does Josh Wolfe file Form 4?
Josh Wolfe has filed Form 4 at EIKN (Eikon Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.